Alternate Day Buprenorphine Administration, Phase XI - 16
NCT ID: NCT00000234
Last Updated: 2016-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Alternate Day Buprenorphine Administration, Phase X - 15
NCT00000233
Alternate-Day Buprenorphine Administration. Phase VIII - 9
NCT00000227
Alternate Day Buprenorphine Administration, Phase XII - 17
NCT00000235
Alternate-Day Buprenorphine Administration. Phase VI - 7
NCT00000225
Alternate Day Buprenorphine Administration, Phase IX - 14
NCT00000232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSSOVER
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Buprenorphine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
25 Years
51 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
University of Vermont
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Warren Bickel, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Vermont
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Treatment Research Center
Burlington, Vermont, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R01-06969-16
Identifier Type: -
Identifier Source: secondary_id
NIDA-06969-16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.